Intetumumab

Intetumumab is a human monoclonal antibody that was being studied for the treatment of solid tumors.[1]

Intetumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetintegrin alpha-V
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6468H10008N1744O2006S40
Molar mass145579.81 g·mol−1
 NY (what is this?)  (verify)

Intetumumab was developed by Centocor, Inc.

Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[2]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.